Search | Aplastic Anemia and MDS International Foundation


Search results

  1. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

    ... myeloid leukemia (AML). Although the hypomethylating agent azacitidine prolongs survival among patients with higher risk ...

    Research Article last updated 02/21/2017 - 9:34am.

  2. SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

    ... treatment with chemotherapy, wide-field radiation, or biologic therapy within 14 days of study entry Patient has received treatment with another investigational agent within 14 days of study entry or concurrent treatment with another ...

    Clinical Trial last updated 06/06/2016 - 2:11pm.

  3. Research Overview - Recent Past Progress and Projections for the Near-Term

    ... the proteins that are made from those genes. Or, we focus on biologic processes that are deregulated to see if there is a way to understand ... made by Lilly. One trial has already started, and the second agent will begin clinical testing in MDS patients later this year. What ...

    Interview last updated 02/10/2014 - 9:40am.